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Background: Because oestrogen receptor α (ERα) regulates E2F1 expression to mediate tamoxifen resistance in
ERα-positive breast cancer cells, we aimed to define the possible roles of ERα and E2F1 in promoting the resistance
of ERα-negative breast cancer cells to 4-hydroxy-tamoxifen (4OHT).
Methods: This study utilised conventional techniques to demonstrate the effects of 4OHT on the expression of
ERα and E2F1 and also examined the individual and combined effects of 4OHT with dipyridamole (DIPY) and
3-O-(3,4,5-trimethoxybenzoyl)-(-)-catechin (TMCG) on the oestrogen-negative MDA-MB-231 breast cancer cell
line using viability assays, Hoechst staining, MALDI-TOF mass spectroscopy, and confocal microscopy.
Results: Despite the ERα-negative status of the MDA-MB-231 cells, we observed that 4OHT efficiently up-regulated ERα
in these cells and that this upregulation promoted E2F1-mediated cell growth. Because E2F1 plays a dual role in cell
growth/apoptosis, we designed a therapy incorporating TMCG/DIPY to take advantage of the elevated E2F1 expression
in these 4OHT-treated cells. 4OHT enhances the toxicity of TMCG/DIPY in these ERα-negative breast cancer cells.
Conclusions: Because TMCG/DIPY treatment modulates the methylation status/stability of E2F1, the results
demonstrate that therapies targeting the epigenetic machinery of cancer cells in the presence of overexpressed
E2F1 may result in efficient E2F1-mediated cell death.
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Define the role of ERα and E2F1 in the resistance of
ERα-negative breast cancer cells to 4-hydroxy-tamoxifen
and develop new therapies to promote E2F1-mediated
apoptosis in this type of breast cancer cell.
Background
Human breast cancer is a heterogeneous disease with
respect to molecular alterations, incidence, survival,
and response to therapy. Tamoxifen has been used for
the systemic treatment of patients with breast cancer
for nearly four decades, and the success of this treatment
is primarily dependent on the presence of oestrogen
receptor-α (ERα) in the breast carcinoma. Approxi-
mately half of patients with advanced ERα-positive* Correspondence: fermontenegro@um.es; neptuno@um.es
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article, unless otherwise stated.disease immediately fail to respond to tamoxifen, and
the disease ultimately progresses to a resistant pheno-
type in the responding patients [1]. The possible causes
for intrinsic and acquired resistance have been attributed
to the pharmacology of tamoxifen, alterations in the struc-
ture and function of the ERα, interactions with the tumour
environment, and genetic alterations within the tumour
cells [2]. Therefore, understanding the role of ERα in the
development and progression of hormone-unresponsive
and receptor-dependent breast cancer is an important step
in the development of future therapeutics [3].
Tamoxifen and newer selective ERα modifiers compete
with estradiol to bind the ERα in multiprotein complexes
that involve several co-repressor proteins. In contrast to
estradiol-bound ERα, the tamoxifen-ERα complex is typic-
ally unable to promote tumour growth due to altered
gene transcription and nongenomic activities of the ERα
[2]. In vitro studies have shown that anti-oestrogen
treatment of breast cancer cells can induce growthntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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inhibitors p21 and p27 [4,5] and cell death by mecha-
nisms that are still being defined [6,7]. The growth
inhibitory effects of anti-oestrogens in ERα-positive
breast cancer cells are profound, and this allowed early
demonstration of a G1 phase site of action for anti-
oestrogens [8,9]. Studies using synchronized cells dem-
onstrated that cells were more sensitive to oestrogens
and anti-oestrogens in the early G1 phase, immediately
following mitosis [10], compatible with a model whereby
oestrogens and anti-oestrogens acting via the ERα regulate
the rate of progression through the early G1 phase of
the cell cycle. Many studies have been published char-
acterising the multiple mechanisms of anti-oestrogen
resistance, and extensive reviews of this topic are avail-
able [1,2,11,12]. These studies underscore the involvement
of numerous signalling pathways in ERα-regulated breast
cancer cell growth and suggest novel targets to improve
the efficacy of anti-oestrogen therapy. However, because
tamoxifen and its derived metabolite 4-hydroxy-tamoxifen
(4OHT) are specifically active against ERα-positive breast
cancer cells, the effects of these drugs in ERα-negative
cells are not well understood. However, it has recently
been indicated that 4OHT promoted the proliferation of
ERα-negative breast cancer cells via the stimulation of
MAPK/ERK and Cyclin D1 expression [13].
In a recent study, we observed that a combined therapy
designed to uncouple adenosine metabolism using dipyrid-
amole (DIPY) in the presence of a new synthetic antifolate
[3-O-(3,4,5-trimethoxybenzoyl)-(-)-catechin; TMCG] sim-
ultaneously and efficiently blocked both the folic and me-
thionine cycles in breast cancer cells, resulting in massive
cell death [14]. The TMCG/DIPY combination acted as an
epigenetic treatment that reactivated RASSF1A expression
and induced E2F1-mediated apoptosis in breast cancer
cells. In addition to modulating DNA methylation and
chromatin remodelling, this combination also induced the
demethylation of the E2F1 transcription factor. Therefore,
we demonstrated that the simultaneous targeting of
DNA and E2F1 methylation was an effective epigenetic
treatment to induce apoptosis in breast cancer cells.
Importantly, the apoptotic effect of this combination
was shown to be independent of the mutational status
of the p53 gene and the levels of expression of ERα, two
factors that determine the sensitivity or resistance of
breast cancer cells to apoptosis [15,16].
Recently, it has been suggested that ERα regulates E2F1
expression to mediate tamoxifen resistance in ERα-positive
breast cancer cells [17]. Because TMCG/DIPY treat-
ment positively influenced E2F1-mediated cell death,
we hypothesised that this combination may represent
an attractive strategy to target overexpressed E2F1 in
these tamoxifen-resistant cells. Consistent with this
hypothesis, we observed that TMCG/DIPY treatmentwas highly effective against MCF7 tamoxifen-resistant
cells, suggesting that this combinational therapy could be
successfully used for the treatment of patients with anti-
oestrogen resistant ERα-positive breast cancers. To extend
the possible application of this therapy to ERα-negative
breast cancers, we sought to define the roles of ERα and
E2F1 in the resistance of ERα-negative breast cancer cells
to 4OHT. We observed that 4OHT efficiently up-regulated
ERα in MDA-MB-231 cells despite their ERα-negative
status and that the upregulation of ERα promoted E2F1-
mediated cell growth. Because E2F1 plays a dual role in cell
growth/apoptosis, we designed a therapy incorporating
TMCG/DIPY to take advantage of the elevated E2F1 ex-
pression in these 4OHT-treated cells. We observed that by
modulating the posttranslational state of E2F1, the TMCG/
DIPY combination was more active in the presence of
4OHT in an ERα-negative breast cancer model.
Methods
Reagents and antibodies
TMCG was synthesised from catechin by reaction with
3,4,5-trimethoxybenzoyl chloride [18]. DIPY, 4OHT,
U0125, and fulvestrant were obtained from Sigma-
Aldrich (Madrid, Spain). Antibodies against the following
proteins were used: β-Actin (Sigma; Monoclonal clone
AC-15), phospho-ATM (Ser1981) (Millipore, Madrid, Spain;
Monoclonal clone 10H11.E12), phospho-Chk2 (Thr68)
(Millipore; Monoclonal clone E126), E2F1 (Millipore;
Monoclonal clones KH20 and KH95), ERα (Millipore;
Monoclonal clone F3-A), and phospho-H2AX (Ser139)
(Millipore; Monoclonal clone JBW301).
Cell culture and apoptosis assays
The MCF-7 and MDA-MB-231 human breast cancer cell
lines were purchased from the American Type Culture
Collection (ATCC) and were routinely authenticated with
genotype profiling according to ATCC guidelines. The
cells were maintained in the appropriate culture medium
supplemented with 10% foetal calf serum and antibiotics.
For experiments in hormone-deprived conditions cells
were maintained for three days in phenol red-free DMEM
plus 2.5% dextran-charcoal-stripped foetal calf serum
(Life Technologies, Barcelona, Spain) and then they
were treated in the presence or absence of 4OHT. Cell
viability was evaluated by a colourimetric assay for
mitochondrial function using the 2,3-Bis(2-methoxy-
4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
(XTT; Sigma) cell proliferation assay. For this assay,
cells were plated in a 96-well plate at a density of
1,000-2,000 cells/well. The compounds were added once
at the beginning of each experiment. The Hoechst staining
method was used to detect apoptosis. Replicate cultures of
1 × 105 cells per well were plated in 6-well plates. The cells
were subjected to the indicated treatments for 72 h. After
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5 μL of Hoechst 33342 solution (Sigma) per well at 37°C
for 10 min and then observed under a fluorescence micro-
scope. Strong fluorescence was observed in the nuclei of
apoptotic cells, while weak fluorescence was observed in
the non-apoptotic cells. The quantification of apoptotic
cells was performed by counting the cells in four random
fields in each well.
PCR analysis
mRNA extraction, cDNA synthesis, and conventional and
semiquantitative real-time PCR (qRT-PCR) were per-
formed as previously described [19]. The primers were
designed using Primer Express version 2.0 software
(Applied Biosystems, Foster City, CA, USA) and synthe-
sised by Life Technologies. The following primers for hu-
man genes were used: β-Actin (forward: 5′-AGA AAA
TCT GGC ACC ACA CC-3′; reverse: 5′-GGG GTG TTG
AAG GTC TCA AA-3′), Apaf1 (forward: 5′-GCT CTC
CAA ATT GAA AGG TGA AC-3′; reverse: 5′-ACT GAA
ACC CAA TGC ACT CC-3′), E2F1 (forward: 5′-GAG
GTG CTG AAG GTG CAG AAG-3′; reverse: 5′-TTG
GCA ATG AGC TGG ATG C-3′), ERα (forward: 5′- TGG
GCT TAC TGA CCA ACC TG -3′; reverse: 5′- CCT GAT
CAT GGA GGG TCA AA -3′), and p73 (forward: 5′-TGG
AAC CAG ACA GCA CCT ACT TCG-3′; reverse: 5′-
CAG GTG GCT GAC TTG GCC GTG CTG-3′).
ChIP assays
A chromatin immunoprecipitation (ChIP) assay was per-
formed using the Magna ChIP™ G kit from Millipore
according to the manufacturer’s instructions. Briefly,
MDA-MB-231 cells were formaldehyde cross-linked, and
the DNA was sheared by sonication to generate fragments
with an average size of 300 to 3,000 bp. The chromatin
was then incubated with anti-ERα or mouse IgG anti-
bodies. DNA from lysates prior to immunoprecipitation
was used as a positive input control. After washing,
elution, and DNA purification, the DNA solution (2 μl)
was used as a template for qRT-PCR amplification
using specific human primers. The following primer
sequences were used for ChIP-PCR: E2F1 (forward: 5′-
GCA AGT TGA GGA TGG AAG AGG TG-3′; reverse:
5′-TGG GGA CAC GGG AAC ATA GG-3′), ERα (for-
ward: 5′-ACC TTA GCA GAT CCT CGT-3′; reverse:
5′-GCT GCT GGA TAG AGG CTG A-3′), and GAPDH
(forward: 5′-CAA TTC CCC ATC TCA GTC GT-3′;
reverse: 5′-TAG TAG CCG GGC CCTACT TT-3′).
Stealth RNA transfection
Specific Stealth siRNAs for E2F1 (HSS103015, HSS103016,
and HSS103017) were obtained from Life Technologies and
transfected into MDA-MB-231 cells using Lipofectamine
2000 (Life Technologies). The treatments were started 24 hafter siRNA transfection. Stealth RNA negative control
duplexes (Life Technologies) were used as control oligo-
nucleotides, and the ability of the Stealth RNA oligonu-
cleotides to knock down the expression of E2F1 was
analysed by western blot 24 h after siRNA transfection.
Western blot analysis
Whole cell lysates were collected by adding SDS sample
buffer. After extensive sonication, the samples were boiled
for 10 min and subjected to SDS-PAGE. The proteins
were then transferred to nitrocellulose membranes and
analysed by immunoblotting (ECL Plus, GE Healthcare,
Barcelona, Spain).
Immunoprecipitation and MALDI-TOF mass spectroscopy
For immunoprecipitation assays, approximately 2.5 ×
107 MDA-MB-231 cells were lysed in 500 μl of lysis buf-
fer (50 mM Tris, pH 8.0, 300 mM NaCl, 0.4% NP40, and
10 mM MgCl2) supplemented with protease and phos-
phatase inhibitor cocktails (Sigma), 2.5 μM trichostatin
(a potent deacetylase inhibitor), and 50 μM 2PCPA
(an irreversible inhibitor of lysine-specific demethylase
1, LSD1). The cell extracts were cleared by centrifuga-
tion (20,000 × g for 15 min) and then diluted with
500 μl of dilution buffer (50 mM Tris, pH 8.0, 0.4%
NP40, and 2.5 mM CaCl2) supplemented with protease
and phosphatase inhibitor cocktails, DNase I (Sigma),
2.5 μM trichostatin and 50 μM 2PCPA. The extracts
were pre-cleared by 30-min incubations with 20 μl of
PureProteome Protein G Magnetic Beads (Millipore) at
4°C with rotation. The E2F1 antibody was then cova-
lently coupled to Dynabeads® (Life Technologies) and
added to the pre-cleared extracts. After immunoprecipita-
tion and elution, the bound proteins were digested with
trypsin according to standard procedures [20]. The data
were recorded and processed with Agilent MassHunter
Workstation Software to obtain the Peptide Mass Finger-
print (PMF). The resulting PMF mass spectra were
searched against the E2F1 protein sequence with car-
bamidomethylation of cysteine as a fixed modification
and phosphorylation of serine residues as variable modifi-
cation. The peptide mass tolerance was set to 50 ppm, and
a maximum of three missed cleavages was allowed.
Microscopy
Confocal microscopy was carried out using a Leica TCS
4D confocal microscope (Wetzlar, Germany). For indir-
ect immunofluorescence studies, preparations of the
cells on glass slides were fixed with cold acetone for
5 min and then washed with PBS. The cells were incu-
bated with 3% bovine serum albumin (BSA) for 20 min
and then 2 h at room temperature with specific primary
antibodies (diluted 1:200 in PBS containing 1% BSA).
The cells were washed three times in PBS and incubated
Montenegro et al. BMC Cancer 2014, 14:539 Page 4 of 12
http://www.biomedcentral.com/1471-2407/14/539for 1 h at room temperature with Alexa Fluor Dyes as sec-
ondary antibodies (Life Technologies). After 3 washes with
PBS, the cells were incubated with 0.01% 4′-6-diamidino-2-
phenylidene (DAPI; Sigma) in water for 5 min. To ensure
antibody specificity, primary antibodies were replaced with
specific IgGs (diluted 1:200) in negative control reactions.
Statistical analysis
In all experiments, the mean ± standard deviation (SD)
values from three to five determinations in triplicate
were calculated. Statistically significant differences were
evaluated using a Student’s t-test. Differences were con-
sidered to be statistically significant at P < 0.05.
Results and discussion
4OHT up-regulates ERα expression in ER-negative breast
cancer cells
Breast cancer cells are classified as either ER-positive or
ER-negative, depending on the presence or absence ofFigure 1 4OHT induces the expression of ERα in MDA-MB-231 cells. M
4OHT or a combination of 1 μM 4OHT and 10 μM U0126 (4OHT/U0126). (A) E
microscopy. The nuclei were counterstained with DAPI (blue), and the merge
assayed by western blot analysis. (C) Semiquantitative determination of ERα m
PCR and represent the number of copies of mRNA for every 1 × 106 copies of
determined by ChIP assays. Immunoprecipitation using anti-ERα or an IgG wa
the input DNA. In this figure: *indicates that P < 0.05 when compared with un
(P < 0.05) when compared to 4OHT-treated cells but non-significant when coER, particularly ERα. Although there are two known iso-
forms of ER, ERα and ERβ [21], much of what we know
about ER-dependent breast cancer has focused on ERα.
In this report, confocal microscopy experiments and
western blot assays (Figure 1A and B) indicated that the
MDA-MB-231 breast cancer cell line did not express
ERα, which was in accordance with its ERα-negative sta-
tus. However, semiquantitative real-time PCR designed
to detect ERα mRNA showed a consistent expression of
this mRNA transcript, estimated to be approximately 3.3
copies of ERα mRNA for every 106 copies of β-actin
(Figure 1C). Although the specificity of the amplification
of this ERα PCR product was verified by melting curve
analysis, this product was barely detectable by agarose
gel electrophoresis (Figure 1C). Although ERα mRNA
was detected in MDA-MB-231 cells, its expression
levels, as expected, were much lower than in the ERα-
positive cell line, MCF7 (approximately 761 copies of
ERα mRNA for every 106 copies of β-actin; Figure 1C).DA-MB-231 cells were treated for 3 days with vehicle (control), 1 μM
Rα protein expression (red) in MDA-MB-231 cells was assayed by confocal
d images are shown. (B) ERα protein expression in MDA-MB-231 cells was
RNA in breast cancer cells. The histograms were obtained by real-time
β-actin. (D) The In vivo binding of ERα protein to the ERα promoter as
s performed in triplicate. The results are presented as the percentage of
treated controls, and **indicates that the differences were significant
mpared to untreated controls.
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cells to ER antagonists with respect to ERα expression is
not well known, we aimed to determine whether 4OHT
can modulate ERα expression in MDA-MB-231 cells by
analysing the ERα mRNA levels in 4OHT-treated cells.
As observed in Figure 1C, 4OHT significantly induced
the expression of ERα by approximately 6-fold compared
to untreated control cells. The ERα PCR product was
sequenced, and the published ERα sequence was con-
firmed (data not shown). Importantly, this increase in
ERα mRNA was accompanied by a significant increase
in ERα protein as determined by confocal microscopy
and western blot experiments (Figure 1A and B). There
are at least two possible mechanisms by which ERα
gene expression may be lost in ERα-negative breast
cancer cells. First, the activators necessary for ERα tran-
scription may not be available or the transcriptional re-
pressors may predominate. Alternatively, the ERα gene
may be selectively methylated and inaccessible to the
existing transcriptional activators [22]. Because 4OHT
has not been identified as a demethylating agent, it
seems more probable that this drug affected the pattern
of ERα transcription by modulating the range of its acti-
vators/repressors on its corresponding promoter. It is
well established that the MAPK-mediated hyperpho-
sphorylation of ERα can contribute to resistance to tam-
oxifen in breast cancer and that serine 118 in ERα is an
important residue for the stimulation of ERα activity by
the selective ER modulator 4OHT [23]. To demonstrate
the involvement of the MAPK signalling pathway in the
4OHT-induced up-regulation of ERα, we used U0126, a
MAP-ERK kinase (MEK) 1/2 inhibitor. As observed in
Figure 1A-C, U0126 inhibited ERα mRNA and protein
expression in cells co-treated with 4OHT. ChIP assays
also indicated that 4OHT increased the occupancy of
ERα on its own promoter and that U0126 completely
abolished this occupation (Figure 1D). It is well known
that phosphorylation of ERα at specific residues can
stimulate ERα activity in a ligand-independent manner
[23]. By this mechanism of action ERα is phosphory-
lated by active kinases, thereby activating ERα to dimer-
ise, bind DNA, and regulate genes [24]. Taken together,
these results indicated that 4OHT may promote this ERα
ligand-independent pathway in ERα-negative breast
cancer cells, activating the MAPK-mediated phosphor-
ylation of ERα, which may contribute to its own expres-
sion (autoregulation) [25].
The up-regulation of ERα by 4OHT contributes to
anti-oestrogen resistance in ER-negative breast cancer cells
ERα-positive breast cancers generally have a better prog-
nosis and are often responsive to anti-oestrogen therapy,
which was the first example of a successful therapy
targeting a specific protein, the ERα. Unfortunately,ERα-negative breast cancers are more aggressive and un-
responsive to anti-oestrogens. Although the transform-
ation of ERα-negative into ERα-positive cells by gene
therapy or ERα gene re-expression are common strat-
egies to restore anti-oestrogen responsiveness [26], we
observed in this study that MDA-MB-231 ERα-negative
cells were intrinsically resistant to 4OHT despite the
overexpression of ERα. Proliferation assays to determine
the concentration and time-dependent effects of 4OHT
on MDA-MB-231, showed that this drug stimulated
cancer cell proliferation at concentrations as low as 1 nM
(Figure 2A). Stimulation of cancer cell proliferation, in
the presence of 4OHT, was also observed in hormone-
deprived conditions, which indicated that this effect was
independent of oestrogens in the culture medium. This
class of resistance to tamoxifen was firstly discovered by
Gottardis and Jordan [27] in MCF7 cells and the results
agree with additional observation in which long term tam-
oxifen treatment of MDA-MB-231 cells increased their
growth and their aggressiveness in animal tumours [28].
ERα-positive tumours are more differentiated and have
lower metastatic potential than ERα-negative tumours [29].
Because this suggests a protective role of the oestrogen
receptor in tumour progression and metastasis, we next
examined whether the 4OHT-induced expression of ERα
resulted in a decreased metastatic potential of MDA-MB-
231. Using a wound healing assay, we observed that the
treatment of MDA-MB-231 with 4OHT greatly increased
the migratory ability of these cells (Figure 2B). These
results indicated that the re-expression of ERα in ERα-
negative breast cancer cells may promote cell growth and
the resistance of these cells to anti-oestrogen therapy.
To determine whether ERα plays a role in 4OHT resist-
ance, we examined the effect of a decreased level of ERα
on the growth of MDA-MB-231 cells. Because the treat-
ment of these cells with U0126 clearly inhibited the ERα
expression induced by 4OHT (Figure 1A-C), we first ana-
lysed whether this drug also inhibited 4OHT-induced cell
proliferation (Figure 2C). As shown in this Figure, U0126
reduced the growth of cells that were treated with 4OHT
and untreated cells to the same extent. These results indi-
cated that the MAPK cascade controls the proliferation of
this breast cancer cell line. It is well known that mem-
brane ER-α plays a role in the temporal coordination of
phosphorylation/dephosphorylation events for the ERKs
in breast cancer cells [30]. Although at the moment we
unknown the mechanism by which 4OHT activates the
MAPK cascade, it is tempting to speculate that in ERα-
negative breast cancer cells may exist some levels of
membrane-bound receptor. Related to this, our group
(in this study) and others [31] have detected consistent ex-
pression of ERα-mRNA in MDA-MB-231 cells; however,
whether this expression may be related to membrane-
bound ERα is actually unknown. More recently, Zhang
Figure 2 Effects of 4OHT on the growth of MDA-MB-231 cells. (A) Concentration- and time-dependent effects of 4OHT on the growth of
MDA-MB-231 cells. The cells were plated in 96-well plates and treated with different concentrations of 4-OHT. After the indicated times, the
viability of the cells was evaluated using the XTT assay. The absorbance reading at 450 nm was proportional to cell viability. The differences in
cell growth after 72 h were statistically significant (P < 0.05) at all the studied 4OHT concentrations when compared to untreated controls
(CN). (B) The migratory ability of MDA-MB-231 cells treated with vehicle (control; CN) or with 1 μM 4OHT was analysed using a wound healing
assay. (C) The effects of U0126 (10 μM) and fulvestrant (10 μM) on the growth of MDA-MB-231 cells treated with vehicle (control; CN) or with
1 μM 4OHT.
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the proliferation of ERα-negative breast cancer cells via
the stimulation of the MAPK/ERK pathway, which ismediated by ERα-36. Therefore, understand how 4OHT
activates the MAPK cascade in ERα-negative breast
cancer cells will require further studies.
Figure 3 ERα regulates E2F1 expression in MDA-MB-231 cells.
(A) The In vivo binding of ERα protein to the E2F1 promoter. ChIP
assays using untreated MDA-MB-231 cells (control; CN) or those
treated for 3 days with 1 μM 4OHT. Immunoprecipitation using anti-
ERα or IgG was performed in triplicate. The results are presented as
the percentage of the input DNA. *indicates that P < 0.05 when
compared to the untreated controls. (B) PCR was used to detect
E2F1 mRNA in untreated MDA-MB-231 cells or MDA-MB-231 cells
treated for 3 days with 1 μM 4OHT. The data shown here are from a
representative experiment repeated four times with similar results.
(C) MDA-MB- cells 231 transfected with siCN or siE2F1 were treated
for 3 days with 1 μM 4OHT when indicated, and cell growth was
monitored 4 days after transfection (3 days after 4OHT treatment).
The expression of E2F1 protein was monitored by western blot (WB),
and β-actin was used as a loading control. The statistical values
represent data from four replicate samples.
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ous levels of ERα, we treated MDA-MB-231 cells with
fulvestrant. Fulvestrant is a potent anti-oestrogen that pos-
sesses extremely high ERα binding affinity and has two
major effects on ERα signalling. First, it blocks ERα sig-
nalling by inhibiting receptor dimerisation and nuclear
localisation and, second, it blocks ERα expression and
ERα-mediated gene transcription [32]. In addition, binding
of fulvestrant to the ERα has been proposed to induce
proteasomal degradation of the aberrant receptor complex
[33]. As observed in Figure 2C, treatment with fulvestrant
reduced the growth of cells treated with 4OHT. All to-
gether, these experiments support the notion that the
effects of 4OHT on cell growth promotion in MDA-MB-
231 cells were dependent on an intact ERα signalling.
ERα regulates E2F1 expression in ER-negative breast
cancer cells to mediate 4OHT resistance
Recently, it has been proposed that ERα regulates E2F1
expression to mediate tamoxifen resistance in ERα-
positive cells [17]. The overexpression of E2F1 has been
shown to be sufficient to promote breast cancer prolif-
eration [34] by regulating the expression of cyclins and
Cdks to mediate the G1-S transition [35]. Although the
E2F1 promoter lacks the classic oestrogen-response elem-
ent 5′-GGTCAnnnTGACC-3′, ERα is known to interact
with several other transcription factors, including Sp1
[36]. In fact, it has been clearly demonstrated that
tamoxifen increases ERα/Sp1 interactions, modulating
E2F1 expression in MCF7 tamoxifen-resistant cells
[17]. Therefore, we performed a ChIP assay to deter-
mine whether 4OHT can promote the recruitment of
ERα to the E2F1 promoter. The results shown in
Figure 3A indicated that compared to the control,
4OHT substantially increased the occupancy of ERα on
the E2F1 promoter (from 0.002% in untreated cells to
0.47% in 4OHT-treated cells with respect to an input
control). Consistent with the ChIP and proliferation
data, semiquantitative RT-PCR analysis indicated that the
expression levels of E2F1 were markedly increased after
exposure to 4OHT conditions. For these experiments,
control cells and those subjected to 72 h of 4OHT
treatment were harvested for gene expression analysis
(Figure 3B). Finally, to determine whether E2F1 con-
tributed to the increased proliferation after 4OHT
exposure, we silenced E2F1 expression in MDA-MB-
231 cells using specific siRNAs (Figure 3C). Although
E2F1 silencing diminished the proliferation of vehicle-
treated cells, 4OHT did not increase cellular proliferation
in E2F1-depleted cells. Collectively, these results suggest
that, in response to 4OHT, ERα regulates E2F1 expression
to mediate both cellular growth and anti-oestrogen resist-
ance. Since the 4OHT:ERα complex usually weakly binds
to any promoter, these results also indicated that 4OHTmight promote the ERα ligand-independent pathway in
which phosphorylated ERα may control the expression
of several genes, including E2F1.
Designing a combined therapy to enhance the E2F1
pro-apoptotic signalling in 4OHT-treated ER-negative
breast cancer cells
The E2F family of transcription factors plays a key role in
the regulation of cell growth, apoptosis, and oncogenic
transformation by mediating the timely expression of
genes involved in these processes [37]. Although the over-
expression of E2F1 has been directly correlated with its
pro-apoptotic activity [38], more recent data indicated
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apoptotic pathways is more related to the posttranslational
processing of this transcription factor [39,40]. Recently,
negative crosstalk between methylation and other post-
translational modifications of E2F1, such as acetylation and
phosphorylation, has been described [39,40]. Thus, methyl-
ated E2F1 is prone to ubiquitination and degradation,Figure 4 The effects of several individual and combined
treatments on γH2AX foci formation in MDA-MB-231 cells.
MDA-MB-231 cells were treated for 3 days with vehicle (control),
1 μM 4OHT, 10 μM TMCG and 5 μM DIPY (TMCG/DIPY) or with the
triple combination TMCG/DIPY/4OHT at the specified concentrations.
MDA-MB-231 cells were examined by immunofluorescence for γH2AX
foci (red) and DAPI (blue). The histograms represent the positive
γH2AX foci cells and the number of γH2AX foci per nucleus in
γH2AX focus-positive cells. In both cases, *indicates that P < 0.05
when compared to untreated cells subjected to 4OHT treatment
and **indicates that P < 0.05 when compared to untreated cells
subjected to 4OHT and TMCG/DIPY treatment.whereas the demethylation of E2F1 favours its P/CAF-
dependent acetylation at lysine residues 117, 120, and 125
[41]. Whether acetylated E2F1 binds to the promoter of
genes required for S phase (to allow cell growth) or to
the promoters of proapoptotic genes (to induce cell
death) may depend on its subsequent phosphorylationFigure 5 The effects of several individual and combined
treatments on E2F1 phosphorylation and ATM/Chk2 activation
in MDA-MB-231 cells. (A) The phosphorylation status of E2F1 in
response to treatments was determined by MALDI-TOF mass
spectroscopy. Peptides were analysed in untreated MDA-MB-231
cells (control) or those treated for 3 days with 1 μM 4OHT; 10 μM
TMCG and 5 μM DIPY (TMCG/DIPY); or 10 μM TMCG, 5 μM DIPY,
and 1 μM 4OHT (TMCG/DIPY/4OHT). The relative intensities of
specific tryptic peptides were normalised to an internal matrix
control. (B) MDA-MB-231 cells subjected to the above-described
treatment were analysed by immunofluorescence for p-ATM (green),
p-Chk2 (red) and DAPI (blue).
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damage, the hyperacetylated E2F1 protein is stabilised
through direct phosphorylation by Chk2 at Ser364 or
ATM kinase at Ser31 [42,43]. Although 4OHT induced
the ERα-mediated expression of E2F1 (Figure 3B), the
treatment of MDA-MB-231 cells with this drug did not
result in visible DNA double strand breaks (DSBs) (as
determined by the absence of phosphorylation of histoneFigure 6 4OHT enhances TMCG/DIPY toxicity in MDA-MB-231 cells. In
4OHT; 10 μM TMCG and 5 μM DIPY (TMCG/DIPY); or 10 μM TMCG, 5 μM D
effect of the 4OHT, TMCG/DIPY and TMCG/DIPY/4OHT treatments on the m
231 cells as determined by bright-field microscopy and fluorescence micro
sent the percentage of viable and apoptotic cells calculated from the imag
0.05 compared to TMCG/DIPY-treated cells. (B) Semiquantitative determina
ments. The estimated relative levels of the specific mRNA with respect to t
to the expression levels in untreated controls. *P < 0.05 compared to the uH2AX at Ser139, Figure 4). Therefore, consistent with
these results, 4OHT did not increase the phosphoryl-
ation of E2F1 at Serines 31 and 364 (Figure 5A). Tryp-
sin digests of E2F1 immunoprecipitated from untreated
and 4OHT-treated MDA-MB-231 cells primary yielded
the peptides (R)LLDSSQIVIISAAQDASAPPAPTGPAA-
PAAGPC(Carbamidomethyl)DPDLLLFATPQAPRPTPSAP
RPALGRPPVK(R) (measured m/z = 6275.2592) and (R)all cases, the cells were treated for 3 days with vehicle (control); 1 μM
IPY, and 1 μM 4OHT (TMCG/DIPY/4OHT). (A) The images show the
orphology (upper panels) and apoptosis (lower panels) of MDA-MB-
scopy after DNA staining with Hoechst 33342. The histograms repre-
es shown above. *P < 0.05 compared to the untreated controls; **P <
tion of p73 and Apaf1 mRNAs in MDA-MB-231 after different treat-
hat of β-actin mRNA were calculated and then compared with respect
ntreated controls.
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correspond to the non-phosphorylated Ser31- and Ser364-
containing peptides, respectively. Taken together, these
data strongly agree with the results showing the resistance
of MDA-MB-231 cells to 4OHT, which resulted in an
enhancement of cell growth but not visible apoptosis.
Recently, we observed that the TMCG/DIPY combin-
ation acted as an epigenetic treatment that reactivated
RASSF1A expression and induced apoptosis in breast
cancer cells. In addition to modulating DNA methyla-
tion and chromatin remodelling, this combination also
induced the demethylation of the E2F1 transcription
factor [14]. Because these agents modulated multiple
aspects of breast cancer cell metabolism and survival,
including the folic acid and methionine cycles and the
methylation status of cells, we observed that the
TMCG/DIPY combination induced the formation of
DNA DSBs characterised by phosphorylation of histone
H2AX at Ser139 (γH2AX) and its accumulation in nu-
clear foci (Figure 4). Here, we observed that this ther-
apy also induced the substantial activation of ATM and
Chk2, which resulted in nuclear focus localisation of
p-ATM and p-Chk2 (Figure 5B). Consistent with these
results, treatment of MDA-MB-231 cells with TMCG/
DIPY resulted in an increase in E2F1 phosphorylation
at Ser31- and Ser364 (Figure 5A); [14]. Because TMCG/
DIPY treatment positively influenced E2F1-mediated
cell death [14], we hypothesised that this combination
might represent an attractive strategy to target over-
expressed E2F1 in 4OHT-treated ER-negative breast
cancer cells.
To test our hypothesis, MDA-MB-231 cells were treated
with the triple TMCG/DIPY/4OHT combination, and the
effects of this combination on cell growth and apoptosis
were compared to those of the double TMCG/DIPY
combination treatment. As observed in Figure 6A,
addition of 4OHT to the double TMCG/DIPY combination
significantly increased the number of apoptotic cells
(from 35% in TMCG/DIPT-treated cells to more than
60% in cell cultures subject to the triple combination).
This increase in apoptosis was also correlated with
cellular damage, as indicated by an increase in the
number of cells that were positive for phosphorylated
histone H2AX (γH2AX) and with an augmented ratio
of γH2AX per nucleus (Figure 4). The analysis of E2F1
phosphorylation at Serines 31 and 364 indicated that
overexpressed E2F1 was fully phosphorylated in cells
subjected to TMCG/DIPY/4OHT therapy (Figure 5A),
which is consistent with the pattern of Chk2 and ATM
activation (phosphorylation) in these cells (Figure 5B).
Consistent with our hypothesis of TMCG/DIPY/4OHT
combination inducing E2F1-mediated apoptosis, we
observed a significant increase of p73 and Apaf1 mRNAs
after treatment (Figure 6B).Conclusions
As described in the introduction, the mutational status
of the p53 gene and/or the levels of expression of ERα
determine the sensitivity or resistance of breast cancer
cells to apoptosis [15,16]. The p53 tumour suppressor
protein is an essential component of the cell response
induced by genotoxic stresses, but the p53 gene is inacti-
vated or mutated in the majority of human tumours. To
overcome these obstacles, genes that can compensate
or bypass cell death defects regardless of the p53 status
are particularly useful. E2F1 and its proapoptotic genes
represent such a group of molecules and therefore have
direct implications as anti-neoplastic therapeutics for
cancers lacking p53 activity. Recently, our research
group has generated novel antifolate drugs that have
successfully been used in combined hypomethylating
therapies against melanoma [19,44] and breast cancer
[14]. Here, we present an experimental therapy that is
effective in breast cancer cells independently of their
p53 and ERα status, and confirm the hypothesis that the
elevation of E2F1 in the presence of genotoxic stress could
represent a valuable therapy against cancers [38]. Because
the demethylation of E2F1 is required for its DNA
damage-induced accumulation and the activation of its
proapoptotic target genes (such as p73, Apaf1 and
Bim, among others), therapies to target the epigenetic
machinery of cancer cells may result in utility to promote
E2F1-dependent apoptosis in p53-deficient tumours.
Because TMCG/DIPY treatment modulates the methy-
lation status and stability of E2F1, we observed that the
4OHT-dependent overexpression of E2F1 positively
influences E2F1-mediated cell death in ERα-negative
breast cancer cells.
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